癌バイオマーカーの世界市場予測

【英語タイトル】Global Cancer Biomarker Market Research Report - Forecast to 2023

Market Research Futureが出版した調査資料(MRF805009)・商品コード:MRF805009
・発行会社(調査会社):Market Research Future
・発行日:2018年2月5日
・ページ数:144
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(印刷不可)USD4,450 ⇒換算¥502,850見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,250 ⇒換算¥706,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

IntroductionMost healthcare professionals use diagnostic tests to clarify and support their clinical decision making. Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body. Biomarkers may be produced naturally by the affected tissue or by immune cells in the body in response to cancer. Biomarkers are found in the blood, stool, urine, tumor tissue, bodily fluids, or other tissues. Mostly, they improve cancer detection and facilitate high-speed non-invasive diagnosis using genomics and proteomics. The factors incorporate comprehension of disease procedure and shed light about the uniqueness of an individual’s tumor at the molecular level. These components are reflected in the changing outline of clinical trials.
The increasing preference for targeted therapies for the treatment of patients suffering from different types of malignant cancers is one of the major factors driving the growth of the market. Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process. The strategic alliances =for biomarker applications in large-stage clinical trials are fueling the growth of this market.
The global cancer biomarker market is segmented on the basis of type, application, and end-user.
Based on biomarker type, the market is further segmented into proteomic and genetic biomarkers.
Based on application, the market is segmented into diagnostic, prognostic, and therapeutic. Based on diagnostic the market is further segmented into imaging and no-imaging.
On the basis of end-user, the market is segmented into pharma and biotech companies, diagnostic tool companies, healthcare IT/big data companies, and clinical laboratories.
The global cancer biomarker market was at USD 10,754.0 million in 2016 and is expected to register a CAGR of 15.8 % during the forecast period.
Key Players
F. Hoffmann-La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Merck & Co., Inc.(U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), PerkinElmer, Inc (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc (U.S.), QIAGEN N.V (Germany), Thermo Fisher Scientific Inc (U.S.), Illumina Inc (U.S.), and others.
Study objectives
To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global cancer biomarker market.
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market, and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global cancer biomarker market
• To provide a detailed analysis of the value chain and supply chain of the global cancer biomarker market
Target Audience
• Pharmaceutical Companies
• Medical Devices Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors
Key Findings
• The global cancer biomarker market is expected to reach USD 29,923.5 million by 2023 at a CAGR of 15.8% from 2017 to 2023
• On the basis of type, protein biomarker type commanded the largest market share of 41.8% in 2016
• On the basis of application, the diagnostic segment is expected to command the largest market share of 45.7% over the review period and is also expected to grow at the fastest CAGR of 16.2% during the forecast period, 2017 to 2023
• The Americas holds the largest share of the global cancer biomarker market which is expected to reach USD 11,736.5 million by 2023
• Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 16.5 % over the forecast period
The report also covers the regional analysis
• Americas
o North America
 U.S.
 Canada
o South America
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia Pacific
• The Middle East & Africa
o United Arab Emirates
o Saudi Arabia
o Oman
o Qatar
o Kuwait
o Rest of Middle East & Africa

【レポートの目次】

Table of Contents:

Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6 Global Cancer Biomarker Market, By Types
6.1 Introduction
6.2 Protein Biomarker
6.3 Genetic Biomarker
6.4 Others
Chapter 7 Global Cancer Biomarker Market, By Application
7.1 Introduction
7.2 Diagnostic
7.2.1 Imaging
7.2.2 Non- Imaging
7.3 Prognostic
7.4 Therapeutic
Chapter 8 Global Cancer Biomarker Market, By End Users
8.1 Introduction
8.2 Pharma & Biotech Companies
8.3 Diagnostic Tool Companies
8.4 Healthcare IT/Big Data Companies
8.5 Clinical Laboratories
Chapter 9. Global Cancer Biomarker Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Becton Dickinson
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 PerkinElmer, Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Bristol-Myers Squibb
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Bio-Rad Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Eli Lilly and Company
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Merck & Co., Inc
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Pfizer Inc.
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.10 GlaxoSmithKline plc.
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 QIAGEN N.V
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
 11.12 Novartis AG
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
11.13 Thermo Fisher Scientific Inc.
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Strategy
11.13.5 Key Developments
11.14 Illumina Inc.
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Strategy
11.14.5 Key Developments
11.15 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Medical End Users Industry
Chapter 13 Appendix

List of Tables:

Table 1 Cancer Biomarker Industry Synopsis, 2017 – 2023
Table 2 Global Cancer Biomarker Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Cancer Biomarker Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 5 Global Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 6 Global Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 8 North America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 9 North America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 11 US Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 12 US Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Market by Type, 2017 – 2023, (USD Million)
Table 14 Canada Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 15 Canada Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 17 South America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 18 South America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 20 Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 21 Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 23 Western Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 24 Western Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)


List of Figures:

Figure 1 Research Process
Figure 2 Segmentation for Global Cancer Biomarker Market
Figure 3 Segmentation Market Dynamics for Global Cancer Biomarker Market
Figure 4 Global Cancer Biomarker market Share, by Type 2016
Figure 5 Global Cancer Biomarker market Share, by Application 2016
Figure 6 Global Cancer Biomarker Market Share, by End Users, 2016
Figure 7 Global Cancer Biomarker Market Share, by Region, 2016
Figure 8 North America Cancer Biomarker Market Share, by Country, 2016
Figure 9 Europe Cancer Biomarker Market Share, by Country, 2016
Figure 10 Asia Pacific Cancer Biomarker Market Share, by Country, 2016
Figure 11 Middle East & Africa Cancer Biomarker Market Share, by Country, 2016
Figure 12 Global Cancer Biomarker Market: Company Share Analysis, 2016 (%)
Figure 13 F. Hoffmann-La Roche AG: Key Financials
Figure 14 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 15 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 16 Becton Dickinson: Key Financials
Figure 17 Becton Dickinson: Segmental Revenue
Figure 18 Becton Dickinson: Geographical Revenue
Figure 19 Abbott Laboratories: Key Financials
Figure 20 Abbott Laboratories: Segmental Revenue
Figure 21 Abbott Laboratories: Geographical Revenue
Figure 22 PerkinElmer, Inc.: Key Financials
Figure 23 PerkinElmer, Inc.: Segmental Revenue
Figure 24 PerkinElmer, Inc.: Geographical Revenue
Figure 25 Bristol-Myers Squibb: Key Financials
Figure 26 Bristol-Myers Squibb: Segmental Revenue
Figure 27 Bristol-Myers Squibb: Geographical Revenue
Figure 28 Bio-Rad Laboratories: Key Financials
Figure 29 Bio-Rad Laboratories: Segmental Revenue
Figure 30 Bio-Rad Laboratories: Geographical Revenue
Figure 31 Bio-Rad Laboratories: Key Financials
Figure 33 F. Hoffmann-La Roche AG: Key Financials
Figure 34 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 35 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 36 Becton Dickinson: Key Financials
Figure 37 Becton Dickinson: Segmental Revenue
Figure 38 Becton Dickinson: Geographical Revenue
Figure 39 Abbott Laboratories: Key Financials
Figure 40 Abbott Laboratories: Segmental Revenue
Figure 41 Abbott Laboratories: Geographical Revenue
Figure 42 PerkinElmer, Inc.: Key Financials
Figure 43 PerkinElmer, Inc.: Segmental Revenue
Figure 44 PerkinElmer, Inc.: Geographical Revenue
Figure 45 Bristol-Myers Squibb: Key Financials
Figure 46 Bristol-Myers Squibb: Segmental Revenue
Figure 47 Bristol-Myers Squibb: Geographical Revenue
Figure 48 Bio-Rad Laboratories: Key Financials
Figure 49 Bio-Rad Laboratories: Segmental Revenue
Figure 50 Bio-Rad Laboratories: Geographical Revenue
Figure 51 Eli Lilly and Company: Key Financials
Figure 52 Eli Lilly and Company: Segmental Revenue
Figure 53 Eli Lilly and Company: Geographical Revenue
Figure 54 Merck & Co., Inc.: Key Financials
Figure 55 Merck & Co., Inc.: Segmental Revenue
Figure 56 Merck & Co., Inc.: Geographical Revenue
Figure 57 Pfizer Inc.: Key Financials
Figure 58 Pfizer Inc.: Segmental Revenue
Figure 59 Pfizer Inc.: Geographical Revenue
Figure 60 GlaxoSmithKline plc: Key Financials
Figure 61 GlaxoSmithKline plc: Segmental Revenue
Figure 62 GlaxoSmithKline plc: Geographical Revenue
Figure 63 QIAGEN N.V: Key Financials
Figure 64 QIAGEN N.V: Segmental Revenue
Figure 65 QIAGEN N.V: Geographical Revenue
Figure 66 Novartis AG: Key Financials
Figure 67 Novartis AG: Segmental Revenue
Figure 68 Novartis AG: Geographical Revenue
Figure 69 Thermo Fisher Scientific Inc.: Key Financials
Figure 70 Thermo Fisher Scientific Inc.: Segmental Revenue
Figure 71 Thermo Fisher Scientific Inc.: Geographical Revenue
Figure 72 Illumina Inc.: Key Financials
Figure 73 Illumina Inc.: Segmental Revenue
Figure 74 Illumina Inc.: Geographical Revenue


【レポートのキーワード】

癌バイオマーカー

★調査レポート[癌バイオマーカーの世界市場予測] (コード:MRF805009)販売に関する免責事項を必ずご確認ください。
★調査レポート[癌バイオマーカーの世界市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆